Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer

Mark D. Pegram, MD
Published: Friday, May 11, 2018



Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Pegram says it is a very exciting time for drug development in the HER2-positive breast cancer space. Recent FDA approvals have added to the armamentarium of treatments for early-stage disease.

In December 2017, the FDA approved pertuzumab in combination with trastuzumab (Herceptin) and chemotherapy as an adjuvant treatment for patients with HER2-positive breast cancer. This was based off the results from the phase III APHINITY trial, which demonstrated a 3-year invasive disease-free survival rate of 94.1% with the pertuzumab regimen compared with 93.2% with trastuzumab, chemotherapy, and placebo.

This was a positive study, but the difficulty with the trial is that it was done in a low-risk population, says Pegram. It met its statistical endpoint with confidence, but Pegram says that the absolute benefit of adjuvant pertuzumab is small.


Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Pegram says it is a very exciting time for drug development in the HER2-positive breast cancer space. Recent FDA approvals have added to the armamentarium of treatments for early-stage disease.

In December 2017, the FDA approved pertuzumab in combination with trastuzumab (Herceptin) and chemotherapy as an adjuvant treatment for patients with HER2-positive breast cancer. This was based off the results from the phase III APHINITY trial, which demonstrated a 3-year invasive disease-free survival rate of 94.1% with the pertuzumab regimen compared with 93.2% with trastuzumab, chemotherapy, and placebo.

This was a positive study, but the difficulty with the trial is that it was done in a low-risk population, says Pegram. It met its statistical endpoint with confidence, but Pegram says that the absolute benefit of adjuvant pertuzumab is small.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x